European Journal of Preventive Cardiology

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity

By Naveed A. Sattar, Mamas A. Mamas, Runjia Li, Hong Liu-Seifert

Randomised trial in 2,539 peopleInterventions

176 weeks, double-blind, placebo-controlled

The paper

Naveed A. Sattar, Mamas A. Mamas, Runjia Li, Hong Liu-Seifert

University of Glasgow

European Journal of Preventive Cardiology, 10 Aug 2026

doi.org/10.1093/eurjpc/zwag408 PubMed 42572119

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity